163 related articles for article (PubMed ID: 26152920)
1. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.
Ichihara E; Lovly CM
Cancer Discov; 2015 Jul; 5(7):694-6. PubMed ID: 26152920
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska Z; Niederst MJ; Karlovich CA; Wakelee HA; Neal JW; Mino-Kenudson M; Fulton L; Hata AN; Lockerman EL; Kalsy A; Digumarthy S; Muzikansky A; Raponi M; Garcia AR; Mulvey HE; Parks MK; DiCecca RH; Dias-Santagata D; Iafrate AJ; Shaw AT; Allen AR; Engelman JA; Sequist LV
Cancer Discov; 2015 Jul; 5(7):713-22. PubMed ID: 25934077
[TBL] [Abstract][Full Text] [Related]
3. Rociletinib in EGFR-mutated non-small-cell lung cancer.
Sequist LV; Soria JC; Goldman JW; Wakelee HA; Gadgeel SM; Varga A; Papadimitrakopoulou V; Solomon BJ; Oxnard GR; Dziadziuszko R; Aisner DL; Doebele RC; Galasso C; Garon EB; Heist RS; Logan J; Neal JW; Mendenhall MA; Nichols S; Piotrowska Z; Wozniak AJ; Raponi M; Karlovich CA; Jaw-Tsai S; Isaacson J; Despain D; Matheny SL; Rolfe L; Allen AR; Camidge DR
N Engl J Med; 2015 Apr; 372(18):1700-9. PubMed ID: 25923550
[TBL] [Abstract][Full Text] [Related]
4. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
He Y
N Engl J Med; 2015 Aug; 373(6):578. PubMed ID: 26244319
[No Abstract] [Full Text] [Related]
5. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
Sequist LV; Rolfe L; Allen AR
N Engl J Med; 2015 Aug; 373(6):578-9. PubMed ID: 26244318
[No Abstract] [Full Text] [Related]
6. Update to Rociletinib Data with the RECIST Confirmed Response Rate.
Sequist LV; Soria JC; Camidge DR
N Engl J Med; 2016 Jun; 374(23):2296-7. PubMed ID: 27195670
[No Abstract] [Full Text] [Related]
7. Lung cancer: a new generation of EGFR inhibition.
Killock D
Nat Rev Clin Oncol; 2015 Jul; 12(7):373. PubMed ID: 25963089
[No Abstract] [Full Text] [Related]
8. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.
Chuang JC; Salahudeen AA; Wakelee HA
Expert Opin Pharmacother; 2016; 17(7):989-93. PubMed ID: 26950414
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance to targeted therapy for lung cancer.
Govindan R
N Engl J Med; 2015 Apr; 372(18):1760-1. PubMed ID: 25923556
[No Abstract] [Full Text] [Related]
10. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
[TBL] [Abstract][Full Text] [Related]
11. Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.
Nukaga S; Yasuda H; Tsuchihara K; Hamamoto J; Masuzawa K; Kawada I; Naoki K; Matsumoto S; Mimaki S; Ikemura S; Goto K; Betsuyaku T; Soejima K
Cancer Res; 2017 Apr; 77(8):2078-2089. PubMed ID: 28202511
[TBL] [Abstract][Full Text] [Related]
12. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
13. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
[TBL] [Abstract][Full Text] [Related]
14. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
Xu Y; Huang Z; Gong L; Fan Y
Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
16. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
[TBL] [Abstract][Full Text] [Related]
18. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
19. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
